Iran Authorizes Emergency Use of Vaccine Developed Jointly with Australia
TEHRAN (Tasnim) – The emergency use of Spikogen, a coronavirus vaccine developed jointly by Iranian and Australian companies, has been authorized by Iranian officials.
Haleh Hamedifar, the CEO of Iranian pharmaceutical company CinnaGen, which has produced Spikogen in collaboration with Australia, said the emergency-use authorization has been granted for the vaccine.
The results of clinical studies on Spikogen indicate that the vaccine has produced a robust immune response in 87% of recipients.
The vaccine has been proved to be safe with an acceptable degree of tolerability, according to the results of the second phase of clinical trials.
The first phase of the tests on Spikogen had been carried out in Australia and the second and third phases began simultaneously in Iran.
Hamedifar had announced in August that CinnaGen company will be producing the vaccine in mass amounts.
Iranian scientists and experts have succeeded in developing several vaccines against the coronavirus, despite the cruel sanctions imposed by the US.
Human injection of the first phase of clinical studies of the first coronavirus vaccine, made by Iranian researchers called COVIran Barekat, began on December 29, 2020.
Iran has already granted emergency use authorization to Russian-made Sputnik V vaccine, Covaxin made by India’s Bharat Biotech, Oxford/AstraZeneca developed by Russia’s R-Pharm Group, AstraZeneca-SKBio made in South Korea and PastuCovac vaccine, produced jointly by Iran’s Pasteur Institute and Cuba’s Finlay Vaccine Institute.
